Concepedia

Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients

Jason J. Schafer, Neha Sheth Pandit, Agnes Cha, Emily Huesgen, Melissa E. Badowski, Elizabeth M Sherman, Jennifer Cocohoba, Ayako Shimada, Scott W. Keith

Open Forum Infectious Diseases · 2020 · 17 citations · 14 references

DOIFull text

Open access

Abstract

Treatment-experienced PWH eligible to switch their ART may experience significant declines in number and severity of DDIs if switched to BIC/FTC/TAF.

References

14

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Manuel Tsiang, G.S. Jones, Joshua Goldsmith et al. · Antimicrobial Agents and Chemotherapy · 2016 · 274 citations · Full text

Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis

Joel E. Gallant, Priscilla Y. Hsue, Sanatan Shreay et al. · The Journal of Infectious Diseases · 2017 · 216 citations · Full text

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 168 citations

, , +9

Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals

Amy C. Justice, Kirsha S. Gordon, Melissa Skanderson et al. · AIDS · 2018 · 100 citations · Full text

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

Jean B. Nachega, Mugavero, Zeier et al. · Patient Preference and Adherence · 2011 · 94 citations · Full text

, , +21